Form 4: Jasper Therapeutics CFO Herb Cross Acquires 50,000 Stock Options

Herb Cross, CFO of Jasper Therapeutics, acquired 50,000 stock options on February 13, 2025, according to a Form 4 filing with the SEC.

Summary

• Herb Cross, the Chief Financial Officer of Jasper Therapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on February 13, 2025, where Cross acquired 50,000 stock options.
• The exercise price of these options is $6.20.
• The options vest over time, with 1/4th vesting on February 13, 2026, and the remaining 1/48th vesting monthly thereafter, contingent upon continuous service.
• The options expire on February 13, 2035.
• Following the reported transaction, Cross directly owns 50,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative. It's a neutral disclosure.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as executives and directors. This allows investors to monitor their activity and gain insights into their confidence in the company's future prospects.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedule described (1/4th after one year, then monthly) is a fairly standard vesting schedule.
• Comparing the size of this grant to similar companies would require analyzing their executive compensation packages.

Stakeholder Impact

• The stock option grant aligns the CFO's interests with those of shareholders, incentivizing him to increase the company's value.
• The dilution effect of the options is minimal.

Key Dates